logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Calvin E Higgens

USPTO Granted Patents = 12

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 68(Granted Patents)


Company Filing History:

goldMedal12 out of 4,449 
 
Eli Lilly and Company
 patents

Years Active: 1976-1981

Loading Chart...
12 patents (USPTO):Explore Patents
1. 4247542 - A-40104 Antibiotics and process for production thereof (1981-01-27),
2. 4191763 - Antibiotic A16886 and process for production thereof (1980-03-04),
3. 4173702 - 7-(5-Amino-5-carboxyvaler-amido)-3-(carbamoyloxymethyl)-7-methoxy-3-cep (1979-11-06),
4. 4132790 - Antibiotic A16886II (1979-01-02),
5. 4129721 - A-40104 antibiotics and process for production thereof (1978-12-12),
6. 4123612 - 7-(5-Am (1978-10-31),
7. 4122168 - Antibiotic A-35512 and process for production thereof (1978-10-24),
8. 4083964 - Antibiotic A-35512 for increasing feed utilization efficiency in an (1978-04-11),
9. 4054564 - 7-(5-Amino-5-carboxyvaleramido)-7-methoxycephalosporanic acid (1977-10-18),
10. 4024246 - Antibiotic A-22082 and process for production thereof (1977-05-17),
11. 3973015 - Antibiotic A16884 (1976-08-03),
12. 3960667 - Antibiotic A23187 and process for preparation thereof (1976-06-01),

Title: **Calvin E. Higgens: Innovator in Antibiotic Development**

Introduction

Calvin E. Higgens, based in Indianapolis, Indiana, is a prominent inventor known for his significant contributions to antibiotic research and development. With a portfolio of 12 patents, Higgens has been at the forefront of innovative solutions in the field of medicinal microbiology.

Latest Patents

Among his latest patents, Higgens developed the A-40104 antibiotic complex, which includes active factors A, B, C, and D. This complex is produced through submerged aerobic fermentation of Clitopilus pseudo-pinsitus. Notably, factor C has been identified as pleuromutilin, a well-known antibiotic. Factors A and B represent novel antibiotics related to pleuromutilin, with factor A being a D-xylose acetal derivative of pleuromutilin. These factors, along with their derivatives, exhibit activity against various gram-positive and gram-negative bacteria, as well as anaerobic bacteria and Mycoplasma. Additionally, Higgens is credited with the antibiotic A16886, which has both antibacterial and anthelmintic properties, derived from the fermentation of Streptomyces clavuligerus NRRL 3585.

Career Highlights

Calvin E. Higgens has made a substantial impact in his field while working at Eli Lilly and Company. His innovative research and dedication to developing antibiotics have placed him among the leading figures in pharmaceutical innovation.

Collaborations

Throughout his career, Higgens has collaborated with noteworthy colleagues, including Karl H. Michel and Marvin Gorman. These partnerships have fostered an environment of creativity and scientific discovery, further advancing the field of antibiotic research.

Conclusion

Calvin E. Higgens is a vital contributor to the realm of pharmaceutical sciences, particularly in the development of new antibiotics. His body of work not only demonstrates his ingenuity but also highlights the collaborative nature of innovation in medicine. With each patent, Higgens continues to pave the way for new treatments that can positively impact global health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…